Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 14, 2024

BUY
$60.67 - $89.12 $3.94 Million - $5.79 Million
65,000 New
65,000 $4.43 Million
Q2 2022

Aug 12, 2022

BUY
$43.23 - $73.83 $648,450 - $1.11 Million
15,000 Added 27.27%
70,000 $4.25 Million
Q1 2022

May 13, 2022

BUY
$53.19 - $79.24 $2.93 Million - $4.36 Million
55,000 New
55,000 $3.45 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.97B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.